Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole
Recruiting now · Phase 4
Conditions studied: Gastroesophageal Reflux Disease
In brief
The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.
Key facts
- Study ID
- NCT06991348
- Run by
- Carnot Laboratories
- People needed
- 128
- Starts
- 2024-07-30
- Expected to finish
- 2025-11-30
- Last updated by the study team
- 2025-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- With endoscopic diagnosis of GERD or NERD (endoscopy ≤ 15 days old)
- With positive impedance pHmetry results (pHmetry ≤ 15 days old)
- With recurrent symptoms of heartburn and regurgitation for a previous period ≥ 3 months old
You may not qualify if…
- With known hypersensitivity to tegoprazan, pantoprazole, or any of the components of each formulation
- Subjects with concomitant administration of atazanavir, nelfinavir or rilpivirine
- Nephropathic and/or hepatopathic subjects (including non-alcoholic hepatitis)
- Subjects with upper gastrointestinal tract bleeding
- Subjects with gastric and/or duodenal ulcer 2 months prior to screening
- Subjects with a history of esophageal or gastric surgery
Where it is running
- Gastrologen S.A. de C.V. — Mexico City, Mexico City, Mexico (enrolling)
- Saluz Investigación, S.C. — Boca del Río, Veracruz, Mexico (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.